Zydus Lifesciences Limited

BSE:532321 Stock Report

Market Cap: ₹1.0t

Zydus Lifesciences Management

Management criteria checks 3/4

Zydus Lifesciences' CEO is Sharvil Patel, appointed in Apr 2017, has a tenure of 7.75 years. total yearly compensation is ₹300.00M, comprised of 60% salary and 40% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth ₹14.86M. The average tenure of the management team and the board of directors is 5.9 years and 7.5 years respectively.

Key information

Sharvil Patel

Chief executive officer

₹300.0m

Total compensation

CEO salary percentage60.0%
CEO tenure7.8yrs
CEO ownership0.001%
Management average tenure5.9yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sharvil Patel's remuneration changed compared to Zydus Lifesciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹43b

Jun 30 2024n/an/a

₹42b

Mar 31 2024₹300m₹180m

₹38b

Dec 31 2023n/an/a

₹30b

Sep 30 2023n/an/a

₹28b

Jun 30 2023n/an/a

₹25b

Mar 31 2023₹263m₹180m

₹20b

Dec 31 2022n/an/a

₹21b

Sep 30 2022n/an/a

₹20b

Jun 30 2022n/an/a

₹22b

Mar 31 2022₹200m₹180m

₹22b

Dec 31 2021n/an/a

₹23b

Sep 30 2021n/an/a

₹23b

Jun 30 2021n/an/a

₹23b

Mar 31 2021₹263m₹180m

₹22b

Dec 31 2020n/an/a

₹18b

Sep 30 2020n/an/a

₹17b

Jun 30 2020n/an/a

₹13b

Mar 31 2020₹250m₹247m

₹12b

Dec 31 2019n/an/a

₹12b

Sep 30 2019n/an/a

₹14b

Jun 30 2019n/an/a

₹17b

Mar 31 2019₹250m₹248m

₹18b

Dec 31 2018n/an/a

₹20b

Sep 30 2018n/an/a

₹20b

Jun 30 2018n/an/a

₹21b

Mar 31 2018₹250m₹248m

₹18b

Compensation vs Market: Sharvil's total compensation ($USD3.49M) is above average for companies of similar size in the Indian market ($USD1.06M).

Compensation vs Earnings: Sharvil's compensation has been consistent with company performance over the past year.

CEO

Sharvil Patel (45 yo)

7.8yrs

Tenure

₹300,000,000

Compensation

Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...

Leadership Team

NamePositionTenureCompensationOwnership
Sharvil Patel
MD & Executive Director7.8yrs₹300.00m0.0015%
₹ 14.9m
Ganesh Nayak
COO & Executive Director7.5yrs₹140.00m0.035%
₹ 349.7m
Punit Patel
President & CEO of America1.3yrsno datano data
Nitinkumar Parekh
Chief Financial Officerno data₹54.31mno data
Arvind Bothra
Head of Investor Relationsno datano datano data
Dhaval Soni
Company Secretary & Compliance Officer5.9yrs₹2.09mno data
Vikram Shukla
President of Parenteral Operationsno datano datano data

5.9yrs

Average Tenure

50yo

Average Age

Experienced Management: 532321's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sharvil Patel
MD & Executive Director27.4yrs₹300.00m0.0015%
₹ 14.9m
Ganesh Nayak
COO & Executive Director7.5yrs₹140.00m0.035%
₹ 349.7m
Pankaj Patel
Non-Executive Chairman29.7yrs₹1.20m74.98%
₹ 757.8b
Apurva Diwanji
Independent Director8.7yrs₹4.00mno data
Mukeshbhai Patel
Non-Executive Non-Independent Director27.4yrs₹4.00m0.0012%
₹ 11.7m
Bhadresh Shah
Independent Non-Executive Director6.1yrs₹4.10mno data
Akhil Monappa
Independent Director2.2yrs₹3.50mno data
Upasana Konidela
Independent Director2.2yrs₹3.50mno data
Shelina Parikh
Independent Directorless than a yearno data0.00044%
₹ 4.4m

7.5yrs

Average Tenure

56yo

Average Age

Experienced Board: 532321's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:37
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zydus Lifesciences Limited is covered by 69 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited